153 related articles for article (PubMed ID: 35654577)
1. Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea.
Rhee Y; Chang DG; Ha J; Kim S; Lee Y; Jo E; Koh JM
Endocrinol Metab (Seoul); 2022 Jun; 37(3):497-505. PubMed ID: 35654577
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study.
Tanaka S; Mizutani H; Tsuruya E; Fukuda R; Kuge K; Okubo N
J Bone Miner Metab; 2021 May; 39(3):463-473. PubMed ID: 33387064
[TBL] [Abstract][Full Text] [Related]
3. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension.
Koh JM; Chung DJ; Chung YS; Kang MI; Kim IJ; Min YK; Oh HJ; Park IH; Lee YS; Kravitz B; Waterhouse B; Nino A; Fitzpatrick LA
Yonsei Med J; 2016 Jul; 57(4):905-14. PubMed ID: 27189284
[TBL] [Abstract][Full Text] [Related]
5. Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia.
Růžičková O; Killinger Z; Kasalický P; Hamilton L; Tyl R; Tomková S; Kalouche-Khalil L
Adv Ther; 2018 Oct; 35(10):1713-1728. PubMed ID: 30191465
[TBL] [Abstract][Full Text] [Related]
6. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
7. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
8. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
9. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial.
Jamshidi A; Vojdanian M; Soroush M; Akbarian M; Aghaei M; Hajiabbasi A; Mirfeizi Z; Khabbazi A; Alishiri G; Haghighi A; Salimzadeh A; Karimzadeh H; Shirani F; Fard MRH; Nazarinia M; Soroosh S; Anjidani N; Gharibdoost F
Arthritis Res Ther; 2022 Jun; 24(1):161. PubMed ID: 35773713
[TBL] [Abstract][Full Text] [Related]
11. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.
Silverman SL; Siris E; Belazi D; Recknor C; Papaioannou A; Brown JP; Gold DT; Lewiecki EM; Quinn G; Balasubramanian A; Yue S; Stolshek B; Kendler DL
Arch Osteoporos; 2018 Aug; 13(1):85. PubMed ID: 30088189
[TBL] [Abstract][Full Text] [Related]
12. Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study.
Kobayakawa T; Miyazaki A; Takahashi J; Nakamura Y
Bone; 2022 Sep; 162():116480. PubMed ID: 35787482
[TBL] [Abstract][Full Text] [Related]
13. Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis.
Xue F; Ma H; Stehman-Breen C; Haller C; Katz L; Wagman RB; Critchlow CW;
Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1107-14. PubMed ID: 23857864
[TBL] [Abstract][Full Text] [Related]
14. Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study.
Baek KH; Chung YS; Koh JM; Kim IJ; Kim KM; Min YK; Park KD; Dinavahi R; Maddox J; Yang W; Kim S; Lee SJ; Cho H; Lim SK
Endocrinol Metab (Seoul); 2021 Feb; 36(1):60-69. PubMed ID: 33677928
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of denosumab treatment for Korean patients with Stage 3b-4 chronic kidney disease and osteoporosis.
Kim JT; Kim YM; Jung KY; Choi H; Lee SY; Kim HJ
Korean J Intern Med; 2024 Jan; 39(1):148-159. PubMed ID: 38145616
[TBL] [Abstract][Full Text] [Related]
16. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of denosumab on back pain-related disability and quality-of-life in patients with vertebral fragility fractures.
Moretti A; de Sire A; Curci C; Toro G; Gimigliano F; Iolascon G
Curr Med Res Opin; 2019 Jan; 35(1):151-155. PubMed ID: 30406685
[No Abstract] [Full Text] [Related]
18. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
[TBL] [Abstract][Full Text] [Related]
19. Denosumab versus romosozumab for postmenopausal osteoporosis treatment.
Kobayakawa T; Miyazaki A; Saito M; Suzuki T; Takahashi J; Nakamura Y
Sci Rep; 2021 Jun; 11(1):11801. PubMed ID: 34083636
[TBL] [Abstract][Full Text] [Related]
20. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.
Nakamura T; Matsumoto T; Sugimoto T; Shiraki M
Osteoporos Int; 2012 Mar; 23(3):1131-40. PubMed ID: 21927920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]